1.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 494F01, NCT00389285
|
|
2.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NN028-1642, EudraCT No: 2006-005751-16, NCT00617253
|
|
3.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NN028-1614, NCT00336986
|
|
4.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: I189, CAN-NCIC-IND189, IND.189, ZYMOGENETICS-CAN-NCIC-IND189, CDR0000560973, NCT00514085
|
|
5.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NN028-1802, EudraCT No: 2007-001506-25, NCT00523380
|
|
6.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: I202, NCT01152788
|
|
7.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 494C10, NCT00095108
|
|
8.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 494E03, NCT00347971
|